MicroRNAs Expression in Response to rhNGF in Epithelial Corneal Cells: Focus on Neurotrophin Signaling Pathway

Chiara Compagnoni 1, Veronica Zelli 1,2, Andrea Bianchi 3✉, Antinisca Di Marco 3✉, Roberta Capelli 1, Davide Vecchiotti 1,2✉, Laura Brandolini 4✉, Anna Maria Cimini 3✉, Francesca Zazzeroni 1, Marcello Allegretti 4✉, Edoardo Alesse 1,4,† and Alessandra Tessitore 1,2,*

1 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, 67100 L’Aquila, Italy; chiara.compagnoni@univaq.it (C.C.); veronica.zelli@univaq.it (V.Z.); roberta.capelli@graduate.univaq.it (R.C.); davide.vecchiotti@univaq.it (D.V.); francesca.zazzeroni@univaq.it (F.Z.); edoardo.alesse@univaq.it (E.A.)
2 Center for Molecular Diagnostics and Advanced Therapies, University of L’Aquila, Via Pietrini, 67100 L’Aquila, Italy
3 Department of Information Engineering, Computer Science and Mathematics, University of L’Aquila, Via Vetoio, 67100 L’Aquila, Italy; andrea.bianchi@graduate.univaq.it (A.B.); antinisca.dimarco@univaq.it (A.D.M.)
4 Dompè Farmaceutici Spa, via Campo di Pile, 1, 67100 L’Aquila, Italy; laura.brandolini@dompe.com (L.B.); marcello.allegretti@dompe.com (M.A.)
5 Department of Life, Health and Environmental Sciences, University of L’Aquila, P.zza S. Tommasi, 67100 L’Aquila, Italy; annamaria.cimini@univaq.it
* Correspondence: alessandra.tessitore@univaq.it; Tel.: +39-086-243-3518; Fax: +39-0862433131
† These authors contributed equally to this work.

Abstract: Purpose. Nerve growth factor efficacy was demonstrated for corneal lesions treatment, and recombinant human NGF (rhNGF) was approved for neurotrophic keratitis therapy. However, NGF-induced molecular responses in cornea are still largely unknown. We analyzed microRNAs expression in human epithelial corneal cells after time-dependent rhNGF treatment. Methods. Nearly 700 microRNAs were analyzed by qRT-PCR. MicroRNAs showing significant expression differences were examined by DIANA-miRpath v.3.0 to identify target genes and pathways. Immunoblots were performed to preliminarily assess the strength of the in silico results. Results. Twenty-one microRNAs (miR-26a-1-3p, miR-30d-3p, miR-27b-5p, miR-146a-5p, miR-362-5p, mir-550a-5p, mir-34a-3p, miR-200b-3p, miR-141-3p, miR-671-3p, miR-324-5p, mir-411-3p, mir-425-3p) were significantly regulated in response to rhNGF. In silico analysis evidenced interesting target genes and pathways, including that of neurotrophin, when analyzed in depth. Almost 80 unique target genes (e.g., PI3K, AKT, MAPK, KRAS, B RAF, RhoA, Cdc42, Rac1, Bax, Bcl2, Fasl) were identified as being among those most involved in neurotrophin signaling and in controlling cell proliferation, growth, and apoptosis. AKT and RhoA immunoblots demonstrated congruence with microRNA expression, providing preliminary validation of in silico data. Conclusions. MicroRNA levels in response to rhNGF were for the first time analyzed in corneal cells. Novel insights about microRNAs, target genes, pathways modulation, and possible biological responses were provided. Importantly, given the putative role of microRNAs as biomarkers or therapeutic targets, our results make available data which might be potentially exploitable for clinical applications.

Keywords: recombinant human NGF (rhNGF); microRNA; neurotrophin signaling pathway; corneal diseases; biomarkers

1. Introduction

Nerve growth factor (NGF) is a member of the neurotrophin family that includes also brain-derived neurotrophic factor (BDNF) and neurotrophins 3 (NT-3), 4/5 (NT-4/5), and 6 (NT-6). It plays a role by involving two classes of trans-membrane receptors: the
high-affinity tropomyosin tyrosine kinase receptor (TrkA) and the low-affinity p75NTR [1]. When bound to NGF, TrkA activates several pathways, such as the Ras-mitogen-activated protein kinase (MAPK), the extracellular signal-regulated kinase (ERK), the phospholipase C gamma (PLC-γ), and the phosphatidylinositol 3 kinase (PI3K). On the other hand, p75NTR activates c-Jun kinase and NF-κB signaling, generates ceramide, and, in absence of co-expressed TrkA, leads cells toward apoptosis [2]. The biological role of NGF not only is crucial for central and peripheral nervous system function and maintenance but also is relevant for non-neuronal cells, such as immune-hematopoietic cells or epithelia. Besides several neuropathies, some studies [3–8] showed NGF clinical application for skin trauma and diseases (e.g., diabetic, pressure, and vasculitic ulcers), or also for ulcers of the eye’s anterior segment [8–13]. The molecule rhNFG (Cenegermin®), structurally identical to the human NGF, has been EMA (European Medicines Agency) and FDA (Food and Drug Administration) approved as first-in-class treatment for neurotrophic keratitis (NK), a rare degenerative corneal disease due to corneal trigeminal innervation defects causing spontaneous injuries and wounds [14–16]. The drug, administered as eye drops, acts directly on corneal epithelium by stimulating cell survival and growth. Furthermore, it promotes production of tears by lacrimal glands, thus providing lubrication and natural protection from pathogens and injury, and supports corneal innervation, usually lost in neurotrophic keratitis. Some side effects, such as hyperemia, ocular and periocular pain, and photophobia, are in general well tolerated by patients. Robust evidence highlights the possibility not only of treating NK with NGF but also possibly treating other corneal pathological conditions, due to the NGF capability of maintaining the homeostasis of the cornea in in vitro, ex vivo, and in vivo models [13,17]. In this regard, a recent phase-IIa study described the safety and efficacy of NGF for improving symptoms and signs of dry eye disease (DED) [18]. NGF and its TrkA receptor are both expressed in the anterior segment of the eye; in addition, NGF is released in the humor aqueous and tears and is produced by conjunctival cells (epithelial, goblet, immune cells, and fibroblasts) [12,13].

To date, the biomolecular response induced by NGF at the corneal level is still unknown. MicroRNAs (miRNAs) are short, non-coding RNA molecules able to post-transcriptionally regulate gene expression. They are transcribed as pri-miRNAs in the nucleus by RNA polymerase II. Pri-miRNAs are subsequently cleaved by Drosophila Rnase III associated with the microprocessor complex subunit DGCR8 (DiGeorge critical region 8), thus generating hairpin pre-miRNA precursors that are moved to the cytoplasm by exportin 5. There, pre-miRNAs are cleaved again by Dicer, generating the mature double-stranded miRNAs that associate with a member of Argonaute family protein to produce the miRNA-induced silencing complex (miRISC), able to induce translation inhibition or mRNA instability and degradation [19]. MiRNAs are involved in maintaining cell homeostasis and fine-tuning fundamental biological processes, such as cell growth, proliferation, apoptosis, and metabolism. Dysregulated expression of miRNAs is observed and strictly linked to relevant human diseases (e.g., viral, immune, neurodegenerative diseases, cancer), thus indicating their relevant role in physio-pathological processes [20,21]. MiRNAs are found not only in cells but also in body fluids, such as blood, saliva, urine, and tears, where they can be released by active (i.e., secretion by exosomes or vesicles) or passive (i.e., cell death) mechanisms. MiRNAs in body fluids are stable and resistant to endogenous Rnase activity, due to the formation of macromolecular complexes (e.g., with Ago2 or HDL) or to exosome encapsulation [22–26]: for this reason, they are considered potentially suitable biomarkers or even therapeutic targets.

In this work, we analyzed miRNA profiling in a human corneal cell line (HCEpiCs) to detect expression levels in response to rhNGF. Among the differentially expressed miRNAs, we identified several miRNAs that were significantly modulated, unveiling interesting target genes and pathways.
2. Results

2.1. MiRNA Expression in HCEpiC Cells in Response to rhNGF

Expression levels of approximately 700 human miRNAs were evaluated in HCEpiCs after rhNGF treatment for 30 min and 12 and 48 h. Cell response to rhNGF was assessed by phosho-ERK1/2 induction and detection by Western blotting (Supplementary Figure S1). Dysregulated miRNAs, identified by comparison with samples from different NGF time points with unstimulated control cells, are represented by volcano plots in Figure 1.

Figure 1. MiRNA expression in HCEpiCs in response to rhNGF. Volcano plots from human microRNA array cards Set (A) (top) and Set (B) (bottom) analysis, representing levels of miRNAs with respect to unstimulated cells (CTRL) (A) and, dynamically, through experimental time points (B). Significant miRNAs IDs are reported close to the corresponding plot. x axis: fold change (RQ, relative quantification, log scale); y axis: p-value (log scale). Horizontal blue line: $p = 0.05$ threshold. Between brackets: miRs not currently listed in the MiRbase database.

Among them, a total of 21 significant microRNAs were differentially expressed and reported above the represented $p = 0.05$ threshold (horizontal line) in at least one of the
comparisons. As shown, most of microRNAs were downregulated after 12 and 48 h with respect to unstimulated cells, whereas upregulation was observed for several miRNAs in cells treated for 48 h, compared with 12 h. Global dynamic expression levels of the abovementioned miRNAs are reported in Table 1. By comparing each NGF-treated sample with untreated cells, no relevant expression regulation was observed after 30 min. Conversely, miR-362-5p was significantly hypo-expressed after 12 h; miR-26a-1-3p and miR-146a-5p after 12 and 48 h; whereas eight miRNAs (miR-30d-3p, miR-27b-5p, miR-550a-5p, miR-34a-3p, miR-1227-3p, miR-27a-5p, miR-222-5p, miR-151a-5p) were significantly hypo-expressed after 48 h. On the other hand, by considering the sequential expression of miRNAs, based on time progression of treatments, miR-146a-5p, miR-449a, let7c-5p, miR-337-5p, miR-29b-3p, miR-200b-3p, and miR-141-3p were significantly hypo-expressed after 12 h with respect to 30 min, whereas six miRNAs showed significant differences after 48 with respect to 12 h (miR-222-5p, miR-411-3p, miR-425-3p, hypo-expressed; miR200b-3p, miR-671-3p, miR-324-5p, hyper-expressed).

Table 1. Dynamic expression of miRNAs significantly dysregulated (n = 21) at least in 1 comparison, after rhNGF treatment. Relative quantification (RQ) data obtained by comparing 30 min and 12 and 48 h NGF-treated vs. untreated cells (NGF30, NGF12, NGF48), NGF 12 h vs. 30 min (NGF12vs30) and NGF 48 vs. 12 h (NGF 48vs12). Green: RQ values expressing significant downregulation, red: RQ values expressing significant upregulation. Significant p-values in bold.

| miRNA miRBase ID | NGF30 p-Value NGF12 p-Value NGF48 p-Value | NGF12vs30 p-Value | NGF48vs12 p-Value |
|------------------|-----------------------------------------|------------------|------------------|
| hsa-let7c-5p     | 7.035 0.248 1.491 0.773 2.485 0.538 0.212 0.003 1.629 0.330 |
| hsa-mir-29b-3p   | 4.379 0.362 0.5 0.645 0.955 0.977 0.114 0.038 1.917 0.536 |
| hsa-mir-449a     | 3.279 0.194 1.199 0.797 1.85 0.436 0.368 0.000 1.548 0.255 |
| hsa-mir-671-3p   | 1.819 0.634 0.399 0.374 3.819 0.234 0.219 0.207 9.616 0.009 |
| hsa-mir-1227-3p  | 1.292 0.823 0.44 0.397 0.08 0.044 0.343 0.361 0.179 0.088 |
| hsa-mir-26a-1-3p | 1.264 0.724 0.285 0.04 0.228 0.025 0.226 0.080 0.799 0.560 |
| hsa-mir-27b-5p   | 1.175 0.870 0.34 0.218 0.102 0.043 0.291 0.225 0.303 0.071 |
| hsa-mir-141-3p   | 1.175 0.867 0.118 0.059 0.514 0.578 0.101 0.048 4.192 0.306 |
| hsa-mir-200b-3p  | 1.139 0.903 0.125 0.106 0.373 0.340 0.109 0.047 2.936 0.049 |
| hsa-mir-425-3p   | 1.043 0.973 0.661 0.649 0.104 0.065 0.631 0.687 0.155 0.023 |
| hsa-mir-550a-5p  | 1.038 0.961 0.311 0.144 0.147 0.018 0.301 0.211 0.471 0.296 |
| hsa-mir-222-5p   | 1.013 0.993 0.388 0.482 0.029 0.042 0.384 0.523 0.073 0.046 |
| hsa-mir-34a-3p   | 0.974 0.976 0.168 0.143 0.097 0.032 0.173 0.158 0.572 0.578 |
| hsa-mir-146a-5p  | 0.973 0.976 0.039 0.015 0.114 0.049 0.04 0.013 2.854 0.125 |
| hsa-mir-151a-5p  | 0.968 0.984 0.236 0.278 0.027 0.038 0.244 0.361 0.111 0.057 |
| hsa-mir-27a-5p   | 0.863 0.909 0.226 0.193 0.032 0.042 0.261 0.289 0.23 0.105 |
| hsa-mir-411-3p   | 0.725 0.980 1.391 0.840 0.203 0.430 1.927 0.980 0.184 0.015 |
| hsa-mir-324-5p   | 0.712 0.722 0.173 0.097 0.446 0.186 0.245 0.221 2.639 0.045 |
| hsa-mir-30d-3p   | 0.682 0.682 0.194 0.304 0.032 0.01 0.285 0.446 0.268 0.394 |
| hsa-mir-362-5p   | 0.504 0.347 0.276 0.029 0.271 0.160 0.548 0.418 0.939 0.940 |

Overall, by considering also not significant (p > 0.05) expression values, most of microRNAs showed iso-expression after 30 min and hypo-expression after 12 and 48 h. However, in the 48 vs. 12 h comparison, expression level increase was observed in nearly half of miRNAs, possibly suggesting the induction of a putative feedback control mechanism to repriminate original conditions.

2.2. Identification of Target Genes and Pathways

To describe the putative functional role of the above-mentioned 21 differentially expressed miRNAs, an in silico analysis was performed by DIANA-miRpath v3.0 (https://dianalab.e-ce.uth.gr/html/mirpathv3/index.php?r=mirpath; accessed 6 July 2021). DIANA-
TarBase and microT-CDS algorithms (genes union function) were used to identify experimentally supported and predicted miRNA/target-mRNA interactions, respectively, as well as significant KEGG pathways, in which target genes were involved (Tables 2 and 3). Among them emerged the ECM-receptor interaction and the focal adhesion pathways, already described in corneal homeostasis and normal physiological functions [27], corneal epithelial cell motility [28], neovascularization [29] and adhesion [30,31], the Hippo signaling pathway, playing a role in limbal cell proliferation, corneal wound healing and regeneration [32,33] and, as expected, the Neurotrophin signaling pathway. The latter was considered for more in-depth analysis: sixty and fifty genes, targeted by 18 and 16 out of 21 miRNAs (miR-337-5p, mir-34a-3p, mir-1227-3p did not show any target gene) were detected by DIANA-TarBase and microT-based analysis, respectively (Table 4). Approximately 80 unique genes were identified by used algorithms, most of them targeted by more than one miRNA (Figure 2). Target genes, as represented in Figure 3, highlighted the involvement of major signaling pathways, such as MAPK, Ras, PI3K/Akt, p53, Jun, and NF-kB, known to induce cell growth, differentiation and survival, regulation of actin cytoskeleton, or apoptosis. Overall, miRNAs differentially expressed in response to rhNGF were able to regulate most of the genes specifically involved in significant signaling pathways included in the neurotrophin-induced molecular circuitries, playing a role in cell survival, proliferation, or, on the other hand, apoptosis.

Table 2. DIANA-TarBase pathway analysis in response to rhNGF. KEGG pathways identified by considering significant dysregulated miRNAs (n = 21), as detected by DIANA-TarBase (experimentally supported) analysis. The pathway analyzed in this study is highlighted in red.

| KEGG Pathway                          | p-Value          | #genes | #miRNAs |
|--------------------------------------|------------------|--------|---------|
| ECM-receptor interaction             | $1.94 \times 10^{-31}$ | 39     | 15      |
| Adherens junction                    | $1.37 \times 10^{-11}$ | 47     | 16      |
| Proteoglycans in cancer              | $1.75 \times 10^{-9}$ | 85     | 19      |
| Prion diseases                       | $3.82 \times 10^{-9}$ | 12     | 15      |
| Viral carcinogenesis                 | $5.99 \times 10^{-9}$ | 91     | 17      |
| Focal adhesion                       | $1.90 \times 10^{-7}$ | 102    | 18      |
| Protein processing in endoplasmic reticulum | $2.99 \times 10^{-7}$ | 87     | 18      |
| Pathways in cancer                   | $1.04 \times 10^{-6}$ | 163    | 19      |
| Fatty acid biosynthesis              | $1.76 \times 10^{-6}$ | 4      | 5       |
| Chronic myeloid leukemia             | $3.63 \times 10^{-6}$ | 42     | 17      |
| Cell cycle                           | $5.44 \times 10^{-6}$ | 62     | 17      |
| Glioma                               | $5.44 \times 10^{-6}$ | 34     | 18      |
| Renal cell carcinoma                 | $5.44 \times 10^{-6}$ | 38     | 19      |
| Hepatitis B                          | $5.79 \times 10^{-6}$ | 66     | 17      |
| Oocyte meiosis                       | $6.01 \times 10^{-6}$ | 55     | 18      |
| Bacterial invasion of epithelial cells | $6.63 \times 10^{-6}$ | 41     | 16      |
| Ubiquitin mediated proteolysis       | $7.71 \times 10^{-6}$ | 70     | 17      |
| Prostate cancer                      | $1.30 \times 10^{-5}$ | 47     | 17      |
| Neurotrophin signaling pathway       | $2.11 \times 10^{-5}$ | 60     | 18      |
| Small cell lung cancer               | $3.09 \times 10^{-5}$ | 46     | 17      |
| PI3K-Akt signaling pathway           | $4.53 \times 10^{-5}$ | 141    | 18      |
Table 2. Cont.

| KEGG Pathway                                      | p-Value          | #genes | #miRNAs |
|--------------------------------------------------|------------------|--------|---------|
| Transcriptional misregulation in cancer          | $7.92 \times 10^{-5}$ | 70     | 19      |
| Hippo signaling pathway                          | $9.95 \times 10^{-5}$ | 59     | 18      |
| Central carbon metabolism in cancer              | 0.000127         | 34     | 16      |
| p53 signaling pathway                            | 0.000134         | 37     | 17      |
| Shigellosis                                      | 0.000227         | 33     | 14      |
| Colorectal cancer                                | 0.000227         | 33     | 16      |
| Lysine degradation                               | 0.000344         | 20     | 14      |
| FoxO signaling pathway                           | 0.000344         | 62     | 17      |
| Endocytosis                                      | 0.000446         | 84     | 17      |
| Acute myeloid leukemia                           | 0.000496         | 29     | 17      |
| Endometrial cancer                               | 0.000515         | 27     | 16      |
| Pancreatic cancer                                | 0.000515         | 34     | 17      |
| TGF-beta signaling pathway                       | 0.000952         | 36     | 17      |
| Epstein–Barr virus infection                     | 0.010142         | 87     | 17      |
| Sulfur metabolism                               | 0.004825         | 5      | 5       |
| Fatty acid elongation                            | 0.005702         | 6      | 6       |
| Non-small cell lung cancer                       | 0.005702         | 27     | 17      |
| Bladder cancer                                   | 0.005702         | 22     | 18      |
| NF-kappa B signaling pathway                     | 0.006256         | 32     | 17      |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 0.006413         | 26     | 16      |
| HIF-1 signaling pathway                          | 0.006698         | 47     | 18      |
| Spliceosome                                      | 0.007512         | 56     | 18      |
| Amoebiasis                                       | 0.011039         | 41     | 14      |
| Sphingolipid signaling pathway                   | 0.011162         | 49     | 18      |
| Regulation of actin cytoskeleton                 | 0.019688         | 79     | 16      |
| AMPK signaling pathway                           | 0.019688         | 53     | 17      |
| Thyroid hormone signaling pathway                | 0.019688         | 52     | 19      |
| Circadian rhythm                                 | 0.023121         | 16     | 13      |
| mRNA surveillance pathway                        | 0.024669         | 40     | 16      |
| RNA transport                                    | 0.024669         | 64     | 18      |
| Pathogenic Escherichia coli infection            | 0.024739         | 26     | 13      |
| Dorso-ventral axis formation                     | 0.024739         | 15     | 15      |
| Insulin signaling pathway                        | 0.024739         | 57     | 16      |
| Hepatitis C                                      | 0.024739         | 53     | 17      |
| N-Glycan biosynthesis                            | 0.037600         | 19     | 14      |
| Prolactin signaling pathway                      | 0.039423         | 32     | 17      |
| Thyroid cancer                                   | 0.048754         | 14     | 16      |
| Melanoma                                         | 0.049562         | 29     | 17      |
Table 3. DIANA-microT-CDS pathway analysis in response to rhNGF. KEGG pathways identified by considering significant dysregulated miRNAs (n = 21), as detected by DIANA-microT-CDS (predicted) analysis. The pathway analyzed in this study is highlighted in red.

| KEGG Pathway                                      | p-Value        | #genes | #miRNAs |
|--------------------------------------------------|----------------|--------|---------|
| ECM-receptor interaction                         | $1.74 \times 10^{-15}$ | 34     | 15      |
| Prion diseases                                   | $1.12 \times 10^{-8}$  | 9      | 9       |
| ErbB signaling pathway                           | $1.12 \times 10^{-8}$  | 46     | 13      |
| Glioma                                           | $3.13 \times 10^{-6}$  | 32     | 13      |
| Focal adhesion                                   | $3.13 \times 10^{-6}$  | 92     | 16      |
| Proteoglycans in cancer                          | $3.13 \times 10^{-6}$  | 84     | 19      |
| Renal cell carcinoma                             | $3.35 \times 10^{-6}$  | 36     | 12      |
| Glycosaminoglycan biosynthesis—heparan sulfate/heparin | $5.01 \times 10^{-6}$  | 14     | 8       |
| Choline metabolism in cancer                     | $1.32 \times 10^{-5}$  | 51     | 14      |
| FoxO signaling pathway                           | 0.000104        | 58     | 14      |
| PI3K-Akt signaling pathway                       | 0.000104        | 127    | 20      |
| Amoebiasis                                       | 0.000116        | 43     | 14      |
| Adherens junction                                | 0.000182        | 37     | 14      |
| Lysine degradation                               | 0.000186        | 19     | 10      |
| mTOR signaling pathway                           | 0.000192        | 33     | 14      |
| Thyroid hormone signaling pathway                | 0.000211        | 49     | 18      |
| Ras signaling pathway                            | 0.000345        | 85     | 17      |
| Rap1 signaling pathway                           | 0.000661        | 84     | 16      |
| Axon guidance                                    | 0.000768        | 51     | 15      |
| Glycosaminoglycan biosynthesis—keratan sulfate   | 0.001064        | 8      | 6       |
| Pathways in cancer                               | 0.001065        | 142    | 18      |
| Adrenergic signaling in cardiomyocytes           | 0.001896        | 54     | 18      |
| p53 signaling pathway                            | 0.004244        | 31     | 14      |
| TGF-beta signaling pathway                       | 0.004617        | 33     | 16      |
| Glycosaminoglycan biosynthesis—chondroitin sulfate/dermatan sulfate | 0.004672        | 8      | 6       |
| Small cell lung cancer                           | 0.005864        | 38     | 12      |
| Neurotrophin signaling pathway                   | 0.005864        | 50     | 16      |
| Hippo signaling pathway                          | 0.006055        | 49     | 15      |
| HIF-1 signaling pathway                          | 0.006421        | 45     | 14      |
| Glycosphingolipid biosynthesis—lacto and neolacto series | 0.006829        | 11     | 8       |
| AMPK signaling pathway                            | 0.007480        | 49     | 18      |
| Prostate cancer                                  | 0.008563        | 38     | 13      |
| Prolactin signaling pathway                      | 0.008642        | 27     | 12      |
| Circadian rhythm                                 | 0.008642        | 17     | 15      |
| cGMP-PKG signaling pathway                       | 0.100938        | 62     | 17      |
Table 3. Cont.

| KEGG Pathway                                      | p-Value   | #genes | #miRNAs |
|---------------------------------------------------|-----------|--------|---------|
| Regulation of actin cytoskeleton                   | 0.012869  | 76     | 15      |
| Phosphatidylinositol signaling system              | 0.014451  | 32     | 13      |
| Biotin metabolism                                  | 0.014567  | 1      | 1       |
| Long-term depression                               | 0.014567  | 26     | 13      |
| Sphingolipid signaling pathway                    | 0.014740  | 44     | 16      |
| Non-small cell lung cancer                         | 0.019923  | 24     | 10      |
| MAPK signaling pathway                             | 0.021152  | 90     | 17      |
| Pancreatic cancer                                  | 0.024846  | 26     | 10      |
| Melanoma                                           | 0.024846  | 30     | 12      |
| Estrogen signaling pathway                         | 0.029488  | 35     | 15      |
| Wnt signaling pathway                              | 0.035309  | 55     | 16      |
| Chagas disease (American trypanosomiasis)          | 0.038162  | 38     | 15      |
| Bacterial invasion of epithelial cells             | 0.042141  | 28     | 13      |
| Adipocytokine signaling pathway                    | 0.043705  | 27     | 13      |
Table 4. MiRNAs and target genes in neurotrophin signaling pathway, as detected by DIANA-TarBase (experimentally supported, in violet), microT (predicted, in light blue), and both (yellow). As shown, several genes were detected by both algorithms. MiRs displaying global down- or upregulation after NGF treatment are represented in green and red, respectively.

| miR-222-5p | miR-21a-3p | miR-21c-3p | miR-466p-5p | miR-648a-3p | miR-414-5p | miR-132-5p | miR-126-3p | miR-428-3p | miR-30b-5p | miR-23b-3p | miR-473-3p | Let-7c-5p |
|------------|------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------|
| CALM1      | ARHGDHA    | ABL1       | PTEN        | AKT3        | ARHGDIB     | MAP2K6      | ABL1        | ARF1        | AKT3        | JNK1        | AKT3       | GNRH1     |
| GNRH2      | AKT1       | GRB2       | P53          | MAP2K6      | RAX         | AKT1        | GRB2        | AKT2        | AKT3        | GRB2        | MPK1      | GNRH2     |
| KDHNS220   | MAPK1      | AKT2       | MAPK3       | CAMK4       | PLCE1       | JNK9        | AKT1        | GRB2        | AKT2        | GRB2        | GSK2B     | NTRK3     |
| MAP2K3     | NTRK2      | RAX         | MAP2K2      | IRAK1       | RAF1        | CALM1       | CAMK4       | CAMK2D      | NTRK3       | RAF1        | IRSK1     | NTRK3     |
| MAPK1      | RAPGEF1    | RCL1       | PTEN        | IRS1        |cbd1         | GBB2        | CRK          | GSK2B       | SOCS1       | TP53        | NTRK3     | NTRK3     |
| SORT1      | BDK2       | CALM1      | SOCS1       | MAP2K1      | CRK          | MAPK3       | CRK          | HES1        | SOCS1       | TP53        | NTRK3     | NTRK3     |
| SOCS2      | CAMK4      | YWHAE      | MAP2K2      | CRK          | PLCG1       | FRS2        | SHC1        | JNK1        | KRAS        | TRAF6       | KDHNS220  | KDHNS220  |
| YWHAE      | CDC42      | NFkB1      | FOXO3       | RHOA        | GSK2B       | JUN         | JUN         | JUN         | JUN         | JUN         | JNK1      | JNK1      |
| FOXO3      | PINK1      | RBF2       | SHC1        | JNK1        | MAP2K1      |                         |                 |             |             |             |             |           |
| RBF2       | PINK1      | GSK2B      | PLCG1       | GSK2B       | KDHNS220    | SORT1       |                         |                 |             |             |             |           |
| JUN        | PTEN       | IRS1       | KDHNS220    | IRS1        | TRAF6       |                         |                 |             |             |             |             |           |
| KDHNS220   | BDK2       | CALM1      | SOCS1       | MAP2K1      | CRK          | MAPK3       | CRK          | HES1        | SOCS1       | TP53        | NTRK3     | NTRK3     |
| MAPK3      | MAPK6      | NRK1       | MAP2K6      | NT1         |                         |             |             |             |             |             |             |           |
| NRK1       | MAP2K6      | P53K3      | MAPK2       | P53K3       |                         |             |             |             |             |             |             |           |
| P53K3      | P53K3      | P53K3      | RPS6KA3     | RPS6KA3     |                         |             |             |             |             |             |             |           |
| BHLA       | PSN1       | RAP1B      | RAC1        | RHOA        |                         |             |             |             |             |             |             |           |
| SOCS1      | SHC1       | RPS6KA2    |                         |             |             |             |             |             |             |             |             |           |
| TP53       | SHC1       | BDK2       |                         |             |             |             |             |             |             |             |             |           |
| YWHAE      | PTPN11     |                         |             |             |             |             |             |             |             |             |             |           |
| PTPN11     |                         |             |             |             |             |             |             |             |             |             |             |           |
| RPS6KA3    |                         |             |             |             |             |             |             |             |             |             |             |           |
| RPS6KA5    |                         |             |             |             |             |             |             |             |             |             |             |           |
| SHC1       |                         |             |             |             |             |             |             |             |             |             |             |           |
| SHC4       |                         |             |             |             |             |             |             |             |             |             |             |           |
| SORT1      |                         |             |             |             |             |             |             |             |             |             |             |           |
| SOCS1      |                         |             |             |             |             |             |             |             |             |             |             |           |
| TP53       |                         |             |             |             |             |             |             |             |             |             |             |           |
2.3. Protein Expression Levels of Target AKT and RhoA

To perform an initial validation of in silico results, expression levels of total AKT and RhoA, two among the identified putative targets, were evaluated. As reported in Figure 2 and Table 4, AKT1, AKT2, and AKT3 resulted in being target genes of miR-29b-3p, miR-27a-5p, and miR-324-5p (AKT1); miR-146a-5p and miR-29b-3p (AKT2); miR-30d-3p, miR-200b-3p, and miR-362-5p (AKT3). On the other hand, RhoA was reported to be regulated by miR-200b-3p and miR-27a-5p. Regarding AKT, as shown in Table 1, the above-mentioned miRs were mainly iso-expressed after 30 min and hypo-expressed after 12 and 48 h with respect to unstimulated cells. Moreover, expression levels of most of them increased after 48 when compared with those observed after 12 h (Table 1). As shown in Figure 4, total AKT expression globally reflects and is coherent with miRNAs’ expression levels, as they are comparable with the control after 30 min and hyper-expressed after 12 and, less markedly, 48 h. Overall, a similar and consistent RhoA protein expression, compared with levels of related miRNA, was observed in cells treated for 30 min and 12 h with rhNGF, followed by a decrease after 48 h (Figure 4). Even though it is known...
that circuitries involving miRNAs/target genes regulation are complex and can be also controlled by other different and multiple molecular interactions, this analysis could, however, be considered as an initial validation of the strength of the in silico results. Of note, RhoA/miR-200b-3p, AKT1/miR-29b-3p, AKT1/miR-27a-5p, AKT2/miR-29b-3p, and AKT2/miR-146a-5p interactions were experimentally supported in in vitro models by different methods (e.g., HITS-CLIP, microarray, luc assay, immunoprecipitation), as reported in TarBase and miRPathDB. The RhoA/miR-200b-3p interaction was further demonstrated in HEK293T cells [34].

Figure 3. Target genes of significant miRNAs in neurotrophin signaling pathway. Colors of boxes as follows: blue: predicted target genes from DIANA-microT analysis; violet: experimentally-supported target genes from DIANA-TarBase analysis; yellow: target genes identified by both DIANA-microT and TarBase algorithms; white: genes not identified as target of significant miRs here described. Arrows as follows: regular line: molecular interaction or relation; dotted line: indirect link or unknown reaction. Modified from DIANA tools/KEGG.
3. Discussion

Human corneal epithelium expresses high-affinity TrkA receptors for NGF and releases growth factors (NGF, BDNF, glial cell derived neurotrophic factor GDNF, ciliary neurotrophic factor CNTF, epidermal growth factor EGF) that produce a positive effect on the survival, differentiation, and maturation of nerve fibers [10,35]. These molecules are the most important mediators of interactions between corneal epithelium and nerves, by activating reciprocally each other to secrete trophic neuropeptides and cytokines for the normal healing of the cornea [35]. For more than one decade, NGF has demonstrated its efficacy in maintaining corneal homeostasis in in vitro, ex vivo, and in vivo models and in preliminary uncontrolled studies on humans as well, where it was described as an effective treatment of corneal neurotrophic lesions [9–13]. NGF has now therapeutic value in ophthalmology, being approved as a first-in-line drug for neurotrophic keratitis (rhNGF, Cenegermin®). It is also under evaluation for other eye diseases of both anterior and posterior eye segments, such as dry eye disease (DED), glaucoma, and retinopathies [12,18,36]. However, very little is known about molecular mechanisms induced by NGF in corneal cells. In this study, we analyzed for the first time the modulation of microRNAs expression in response to rhNGF in an in vitro model of corneal epithelial cells. MicroRNAs are a class of short, non-coding RNA molecules crucial in the regulation, at the epigenetic level, of post-transcriptional gene expression. Their interaction with target genes is dynamic and varies depending on multiple factors, such as the relative quantity of miRNAs and related target mRNAs, affinity of their interactions, or subcellular location. Several miRNAs have been described in corneal physiology, disease, and potential therapy [37]. In this work, after analyzing a remarkable part of the human miRNome, we characterized a group of 21 miRNAs showing significant expression level variations after rhNGF treatment, most of which were never described in corneal cells. In this regard, the data in the literature related to cornea are available only for miR-146a-5p: in two studies [38,39], miR-146a hyper-expression was correlated with delayed corneal wound healing in telomerase-immortalized HCECs (human corneal epithelial cells) and LECs (limbal epithelial cells) models, most probably depending on the inhibition of activated p38 MAPK and EGFR, known as mediators of epithelial wound closure. MiR-146a was found hyper-expressed in patients with Sjögren’s syndrome, a condition char-
acterized by dry eye, and in Sjogren-prone mice as well [40,41]. In addition, Movahedan et al. [42] described a Notch1-mediated decrease in early-stage corneal wound healing, and a recent study by using human primary limbal epithelial cells [43] demonstrated that miR-146a increased Notch1 by Numb downregulation. In accordance, both TargetsCan human v7.2 (http://www.targetscan.org/vert_71/; accessed 6 October 2021) and miRDB (http://www.mirdb.org/; accessed 6 October 2021) databases report miR-146a-5p/Numb interaction, and previous studies on other cell types demonstrated the miR-146a-mediated Numb downregulation as well [44,45]. In this context, the NGF-induced miR-146a expression decrease detected in our in vitro model might lead to hypothesize a putative role of the neurotrophin in rebalancing corneal pathophysiological conditions by promoting, for instance, wound healing in the case of cornea damage. However, on the other hand, another study on a corneal alkali burn rat model showed that the treatment with miR-146a-overexpressing bone marrow mesenchymal stem cells induced a protective and repair effect by decreasing the levels of p65-NF-κB/PCNA (proliferating cell nuclear antigen) and by inhibiting apoptosis, inflammatory cytokine secretion and corneal neovascularization [46].

The twenty-one dysregulated miRNAs were further analyzed in silico by DIANA tools, and several significant pathways and target genes, predicted and/or experimentally validated, were identified. We focused our attention on the neurotrophin signaling pathway: approximately 80 unique target genes were identified, most of them targeted by more than one miRNA and playing a role in relevant signaling processes (i.e., MAPK, PI3K/AKT, NF-κB) and cell functions (e.g., differentiation, survival, or apoptosis) already described in corneal physiological and pathophysiological processes as being at the base of injury, wound healing, and regeneration [47–50]. The 80 genes represent the majority of those involved in the neurotrophin signaling pathway, as shown in the modified KEGG scheme (Figure 3), confirming the potential strong impact of miRNAs here identified on the modulation of specific NGF-induced cell responses. To date, few data about the NGF-mediated regulation of the above-mentioned target genes and related biological processes in corneal cells are available in literature. A study described epithelial corneal cells proliferation in response to cyclin D, PI3K/AKT, MAPK/Erk pathway activation (AKT and MAPK are target genes in our analysis) [51]; furthermore, in a corneal wound healing model of aquaporin5 knock-out mice, NGF was shown to induce epithelial and nerve regeneration by activating the Akt signaling pathway [52]. In vitro expansion of phenotypic and functional corneal endothelial cells able to contribute to restore corneal endothelium was described in a rabbit model in response to the combined activation of PI3K/Akt and Smad2 [53]. Park et al. [54] demonstrated NGF-induced attenuation of apoptosis and downregulation of Bax (here identified as target gene as well), NF-kB-p65, IL-1β, TNF-α, and cleaved-caspase 3 and reduction in inflammation in a diabetic high-glucose human corneal epithelial model. GTPase RhoA, Rac1, and Cdc42 proteins, identified as targets in this analysis, were described to maintain corneal functions and barrier homeostasis: Zhu et al. [55] observed expansion of HCECs monolayers due to RhoA-ROCK-non-canonical BMP (bone morphogenic protein)-NF-kB pathway activation, following p120 catenin and Kaiso proteins knocking-down; Cui et al. [56] demonstrated in vivo that the exposition to airborne particulate can induce delayed corneal epithelium wound closure by suppressing RhoA activity; Ortega et al. [57] showed that the activation of RhoA and Rac1 in response to stimulus disrupting endothelial cell–cell junctions preserved corneal endothelial barrier function; Rac1 was described as an important factor for corneal cell adhesion, motility promotion by fibronectin, and wound healing [58]; Cdc42 was able to promote wound repair and significantly improve the migration of human corneal epithelial cells in monolayer scratch assay [59]. Other genes here identified were the subject of previous studies: Rogge et al. [60] demonstrated the potential therapeutic efficacy of soluble Fas ligand (FASLG), which decreased inflammation and angiogenesis in primary and recurrent forms of herpetic stromal keratitis in a mouse model; a study based on a proteomic approach aimed at identifying putative biomarkers in tears from patients affected by DED secondary to rheumatoid arthritis highlighted reduced expression of SHC transforming isoform 1.
(SHC1) in 63% of cases [61]. Taken together, the data in the literature so far available are overall consistent with the results obtained in this study: in fact, all of the above-mentioned genes are targeted by miRNAs that are hypo-expressed after NGF treatment, leaving one to hypothesize about the expression increase in protein products and evidencing a putative NGF-induced biological response on corneal cells in the presence of injury. Of note, due to the complexity of miRNA-mediated gene expression regulatory networks, in which multiple and different molecular mechanisms may be involved, we cannot exclude that other regulatory systems (e.g., DNA methylation or histone modification) or direct effects on genes/proteins involved in biochemical signaling may be implicated and contribute to rhNGF-induced response. However, although data here have shown a need further experimental validation, the analysis of AKT and RhoA protein expression in response to NGF treatments might be considered a preliminary demonstration of the strength of in silico results.

Overall, this research makes available interesting and novel insights in terms of NGF-regulated miRNAs and target genes identification, shedding light on some still unknown and possible biological mechanisms induced by NGF in corneal epithelial cells. The emerging role of microRNAs in putatively modulating and directing the response of corneal epithelial cells to NGF here evidenced is potentially of relevant impact. MicroRNAs are RNase-protected and very stable molecules, even under difficult conditions or extended storage. For this reason, they are considered to be suitable biomarkers for diagnosis, and if dysregulated, they are considered to be therapy targets to reestablish normal physiological conditions. Innovative therapeutic strategies are based on the use of synthetic miRNA inhibitors or mimics molecules, which, when appropriately delivered, can inhibit or restore normal expression levels and functions of hyper-expressed or downregulated miRs [62]. In this scenario, the characterization of miRNAs dysregulation in corneal biological processes, or in disease pathogenesis and progression, might be of translational value, this body part being easily accessable by targeted therapies, and the eye being one of the few organs where gene silencing could be successfully achieved. This innovative therapeutic approach is under evaluation for some eye disorders in several, mainly preclinical, trials. Simple local administration of naked siRNAs, a class of double stranded RNA fully complementary to mRNA and able to silence genes by endonucleolytic cleavage, demonstrated reduced systemic side effects and toxicity [63]. Besides the diseases that are high-impact and studied more in-depth, such as cancer or cardiovascular diseases [64-67], the possibility of using miRNAs for the treatment of anterior and/or posterior eye segment disorders is currently under investigation [68-70]. Arguably, this requires more exhaustive understanding of their specific role in this organ and related diseases. In this scenario, by improving knowledge in the field, miRNAs might represent in the future a suitable method for the treatment of ocular disorders.

In conclusion, this study analyzed the effects of rhNGF on epithelial corneal cells by focusing the attention on miRNAs expression levels, target genes, and pathways, and the study provided novel insights about molecules and possible responses induced by this neurotrophin in epithelial corneal tissue, potentially exploitable for clinical applications.

4. Materials and Methods

4.1. Cell Culture and Treatment

Human corneal epithelial cells (HCEpiC) (P10871, Innoprot, Derio, Bizkaia, Spain) were cultured in corneal epithelial cell medium (Innoprot, Derio, Bizkaia, Spain) supplemented with 5% fetal bovine serum (Gibco by Life Technologies Limited, Paisley, UK), 1% corneal epithelial cell growth supplement (CEpiCGS) (Innoprot), and 1% penicillin/streptomycin solution (Innoprot, Derio, Bizkaia, Spain). Cells were grown on T75 flasks precoated with collagen I (Corning® BioCoat™ Collagen I Cultureware, Glendale, Arizona, USA) and maintained in humidified atmosphere at 37 °C with 5% CO2. The medium was changed every 3 days until the culture was approximately 70% confluent, and subsequently every day until the culture was approximately 80% confluent. Then,
4.2. Total RNA Isolation

Total RNA, including the fraction less than 200 nucleotides in length, was isolated from HCEpiCs using the mirVana isolation kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s protocol. The concentration of RNA was assessed by Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA), and RNA samples were stored at −80 °C until use.

4.3. Reverse Transcription and TaqMan miRNA Array

Total RNAs from treated samples and control were reverse transcribed using the Megaplex RT primer Human Pool A and B set v3.0 (Applied Biosystem, Thermo Fisher Scientific, Waltham, MA, USA) and the TaqMan miRNA RT kit (Applied Biosystem, Thermo Fisher Scientific, Waltham, MA, USA). The reverse transcription reaction was performed by using 700 ng of total RNA, according to the manufacturer’s instructions. Subsequently, three replicated samples from each experimental time point and control cells were run on microfluidic TaqMan Array Human MicroRNA cards v3.0 (set A and B) (Applied Biosystems), according to the manufacturer’s instructions. These 384-well cards are preconfigured for a total of 754 unique assays specific to human miRNAs. Samples were analyzed on a ViiA7 instrument (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA), and data were processed by QuantStudio Real-Time PCR software v1.2 (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). MicroRNA’s expression levels (RQ, relative quantification) were evaluated by comparative assay (2^−ΔΔCt) [72]. snU6 RNA was used as endogenous control.

4.4. Statistics and Target Genes/Pathways Analysis

Comparative data analysis was carried out by ExpressionSuite v1.1 (Thermo Fisher, Waltham, MA, USA). To make the study as stringent as possible, the confidence interval was set as >95%, and wells with flag(s) (abnormal/doubt signals and/or parameters) were omitted from the analysis. Global distribution of microRNAs’ expression was visualized by volcano plots. Among the differentially expressed (RQ, fold change ≤0.5 or ≥2), a list of significant miRs (p < 0.05) was generated by using the proprietary algorithm (Thermo Fisher, Waltham, MA, USA) based on ΔCt. Significant miRNAs were further analyzed by DIANA tools (DIANA-miRpath v3.0,-microT-CDS,-TarBase v7.0) [73] to identify predicted (microT-CDS database) [74] and/or experimentally supported (TarBase database) [75] target genes and pathways. We used KEGG database annotation with standard statistics and genes union settings for an exploratory functional analysis. MiRNAs and target genes were included in a Neo4J graph database [76] and elaborated to represent relationships. qRT-PCR data files are presented in Supplementary Materials.

4.5. Western Blot Analysis

To assess the efficacy of rhNGF treatment under our cell system conditions, immunoblotting was performed to investigate the expression of phosphorylated ERK1 and ERK2 MAP kinases.

HCEpiCs were lysed in 50 μL modified RIPA Buffer (PBS 1X, NP40 1%, sodium deoxycholate 0.5%, SDS 1%, Complete-Mini protease inhibitor cocktail tablet (Roche Diagnostics, Basel, Switzerland), PMSF 10 mg/mL, aprotinin 10 mg/mL, and sodium orthovanadate 0.1 M (Sigma-Aldrich, Burlington, MA, USA). Cell lysates were incubated on ice for 30 min and then centrifuged at 14,000 × g for 15 min at 4 °C. The supernatant was recovered and stored at −80 °C until use.

Protein concentration was determined using the standard BCA control with the Pierce BCA protein assay kit, according to the manufacturer’s instructions.
A total of 30 µg of protein extracts was loaded onto an SDS-PAGE and subjected to electrophoresis; then proteins were electro-transferred to a 0.2 µm nitrocellulose membrane (Amersham™ Protran™ Premium, Ge Healthcare, Little Chalfont, Buckinghamshire, UK) and hybridized overnight at 4 °C with the phospho-p44/42 MAPK (ERK1/2) monoclonal antibody (#4370, Cell Signaling Technology, Danvers, MA, USA). The membrane was washed in TBS-T and incubated one hour at room temperature with the goat anti-rabbit IgG-HRP secondary antibody (sc-2030, Santa Cruz Biotechnology, Dallas, Texas, USA). After signal detection, the membrane was stripped (Restore™ Western Blot Stripping Buffer, Thermo Fisher Scientific, Waltham, MA, USA) for 30 min at 37 °C, then it was incubated again overnight at 4 °C with the p44/42 MAPK (ERK1/2) monoclonal antibody (#4695, Cell Signaling Technology, Danvers, MA, USA) and with secondary antibody as previously described. Actin (sc-1615, Santa Cruz Biotechnology, Dallas, Texas, USA) was used as endogenous control. The same procedure was followed with anti-AKT antibody (#9272, Cell Signaling Technology, Dallas, Texas, USA), recognizing AKT1, 2 and 3 isoforms, and anti-RhoA (#2117, Cell Signaling Technology, Dallas, Texas, USA); chemiluminescent detection system (SuperSignal™ West Pico Plus, Thermo Scientific, Waltham, MA, USA) and ChemiDoc XR + (Bio-Rad, Hercules, California, USA) system or autoradiography films were used to detect signals. Bands corresponding to proteins of interest were scanned and quantified by densitometry using ImageJ software (https://imagej.nih.gov/ij/ accessed 6 October 2021).

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/ijms23073597/s1.

Author Contributions: Conceptualization, E.A. and A.T.; methodology, C.C. and V.Z.; software, A.B. and A.D.M.; validation, C.C. and V.Z.; formal analysis, C.C., V.Z., R.C. and D.V.; investigation and data curation, C.C., V.Z., R.C. and D.V.; writing—original draft preparation, C.C. and V.Z.; writing—review and editing, L.B., A.M.C., F.Z., M.A., E.A. and A.T.; supervision, project administration, and funding acquisition, E.A. and A.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Project n°230-FCS_21 DM 05.03.2018—“accordo innovazione s.d.v.”—“Identification of new compounds for treatment of eye and ear diseases”, Decree of Italian Ministry for Economical Progress 2018 to E.A. and by 07_CONTRACT_DOMPE_TESSITORE for the project entitled “MicroRNA expression analysis in response to different NGF bioformulations in vitro corneal cell models” to A.T.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

Acknowledgments: C.C. was supported by PON 2014-2020 Research and Innovation PhD program; V.Z. and D.V. were supported by PON-AIM 2014-2020 Research and Innovation.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Wiesmann, C.; de Vos, A.M. Nerve growth factor: Structure and Function. Cell Mol. Life Sci. 2001, 58, 748–759. [CrossRef] [PubMed]
2. Aloe, L.; Rocco, M.L.; Bianchi, P.; Manni, L. Nerve growth factor: From the Early Discoveries to the Potential Clinical Use. J. Transl. Med. 2012, 10, 239. [CrossRef] [PubMed]
3. Bernabei, R.; Landi, F.; Bonini, S.; Onder, G.; Lambase, A.; Pola, R.; Aloe, L. Effect of topical application of nerve-growth factor on pressure ulcers. Lancet 1999, 354, 307. [CrossRef]
4. Tuveri, M.; Generini, S.; Matucci-Cerinic, M.; Aloe, L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet 2000, 356, 1739–1740. [CrossRef]
5. Chiaretti, A.; Piastra, M.; Caresta, E.; Nanni, L.; Aloe, L. Improving ischaemic skin revascularisation by nerve growth factor in a child with crush syndrome. Arch. Dis. Child. 2002, 87, 446–448. [PubMed]
6. Landi, F.; Aloe, L.; Russo, A.; Cesari, M.; Onder, G.; Bonini, S.; Carbonin, P.U.; Bernabei, R. Topical treatment of pressure ulcers with nerve growth factor: A Randomized Clinical Trial. Ann. Intern. Med. 2003, 139, 635–641. [CrossRef]
7. Generini, S.; Tuveri, M.A.; Matucci Cerinic, M.; Mastini, F.; Manni, L.; Aloe, L. Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. *Exp. Clin. Endocrinol. Diabetes* **2004**, *112*, 542–544. [CrossRef]

8. Liu, Z.; Wu, H.; Huang, S. Role of NGF and its receptors in wound healing (Review). *Exp. Ther. Med.* **2021**, *21*, 599. [CrossRef]

9. Lambiase, A.; Rama, P.; Bonini, S.; Capriogiorgio, G.; Aloe, L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. *N. Engl. J. Med.* **1998**, *338*, 1174–1180.

10. Lambiase, A.; Rama, P.; Bonini, S.; Miserà, A.; Aloe, L. Nerve growth factor promotes corneal healing: Structural, Biochemical, and Molecular Analyses of Rat and Human Corneas. *Investig. Ophthalmol. Vis. Sci.* **2001**, *40*, 1063–1069.

11. Bonini, S.; Lambiase, A.; Rama, P.; Capriogiorgio, G.; Aloe, L. Topical treatment with nerve growth factor for neurotrophic keratitis. *Ophthalmology* **2020**, *107*, 1347–1351. [CrossRef]

12. Lambiase, A.; Mantelli, F.; Sacchetti, M.; Rossi, S.; Aloe, L.; Bonini, S. Clinical applications of NGF in ocular diseases. *Arch. Ital. Biol.* **2011**, *149*, 283–292. [CrossRef] [PubMed]

13. Lambiase, A.; Sacchetti, M.; Bonini, S. Nerve growth factor therapy for corneal disease. *Curr. Opin. Ophthalmol.* **2012**, *23*, 296–302. [CrossRef] [PubMed]

14. Versura, P.; Giannaccare, G.; Pellegrini, M.; Sebastiani, S.; Campos, E.C. Neurotrophic keratitis: Current Challenges and Future Prospects. *Eye Brain* **2018**, *10*, 37–45. [CrossRef]

15. Bonini, S.; Lambiase, A.; Rama, P.; Filatori, I.; Allegretti, M.; Chao, W.; Mantelli, F.; REPARO Study Group. Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. *Ophthalmology* **2018**, *125*, 1468–1471. [CrossRef]

16. Bonini, S.; Lambiase, A.; Rama, P.; Sinigaglia, F.; Allegretti, M.; Chao, W.; Mantelli, F.; REPARO Study Group. Phase II Randomized, Double-Blinded, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. *Ophthalmology* **2018**, *125*, 1332–1343. [CrossRef]

17. Eftimiadi, G.; Soligo, M.; Manni, L.; Di Giuda, D.; Calcagni, M.L.; Chiaretti, A. Topical delivery of nerve growth factor for treatment of ocular and brain disorders. *Neural Regen. Res.* **2021**, *16*, 1740–1750. [CrossRef]

18. Sacchetti, M.; Lambiase, A.; Bonini, S.; Sacchetti, M.; Rossi, S.; Aloe, L.; Bonini, S. Clinical applications of NGF in ocular diseases. *Curr. Opin. Ophthalmol.* **2012**, *23*, 296–302. [CrossRef] [PubMed]

19. O’Brien, J.; Hayward, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front. Endocrinol.* **2018**, *9*, 402. [CrossRef]

20. Li, Y.; Kowdley, K.V. MicroRNAs in common human diseases. *Genom. Proteom. Bioinform.* **2012**, *10*, 246–253. [CrossRef]

21. Condrat, C.E.; Thompson, D.C.; Barbu, M.G.; Bugnar, O.L.; Boboc, A.; Cretoiu, D.; Suciu, N.; Cretoiu, S.M.; Voinea, S.M.; Voinea, S.C. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. *Cells* **2020**, *9*, 276. [CrossRef] [PubMed]

22. Etheridge, A.; Lee, I.; Hood, L.; Galas, D.; Wang, K. Extracellular microRNA: A New Source of Biomarkers. *Int. J. Mol. Sci.* **2022**, *23*, 3597.

23. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.; Pogosova-Agadjanyan, E.L.; Stirewalt, D.L.; et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 5003–5008. [CrossRef] [PubMed]

24. Vickers, K.C.; Palmisano, B.T.; Shoucri, B.M.; Shamburek, R.D.; Remaley, A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat. Cell. Biol.* **2011**, *13*, 423–423. [CrossRef] [PubMed]

25. Li, L.; Zhou, D.; Huang, L.; Zhang, J.; Bian, Z.; Chen, X.; Liu, Y.; Zhang, C.Y.; Zen, K. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. *PLoS ONE* **2012**, *7*, e46957. [CrossRef]

26. Sanz-Rubio, D.; Martin-Burriel, I.; Gil, A.; Cubero, P.; Forner, M.; Khalyfa, A.; Marin, J.M. Stability of Circulating Exosomal miRNAs in Healthy Subjects. *Sci. Rep.* **2018**, *8*, 10306. [CrossRef]

27. Poux, A.E.; Greiner, M.A.; Coussa, R.G.; Jiao, C.; Han, I.C.; Skeie, J.M.; Fingert, J.H.; Mullins, R.F.; Sohn, E.H. Cell-Matrix Interactions in the Eye: From Cornea to Choroid. *Cells* **2021**, *10*, 687. [CrossRef]

28. Kimura, K.; Kawano, S.; Mori, T.; Inoue, J.; Hadachi, H.; Saito, T.; Nishida, T. Quantitative analysis of the effects of extracellular matrix proteins on membrane dynamics associated with corneal epithelial cell motility. *Investig. Ophthalmol. Vis. Sci.* **2010**, *51*, 4492–4499. [CrossRef]

29. Barbariga, M.; Vallone, F.; Mosca, E.; Bignami, G.; Magagnotti, C.; Fonteyne, P.; Chiappori, F.; Milanesi, L.; Rama, P.; Andolfo, A.; et al. The role of extracellular matrix in mouse and human corneal neovascularization. *Sci. Rep.* **2019**, *9*, 14272. [CrossRef]

30. Kowtharapu, B.S.; Murin, R.; Jünemann, A.G.M.; Stachs, O. Role of Corneal Stromal Cells on Epithelial Cell Function during Wound Healing. *Int. J. Mol. Sci.* **2018**, *19*, 464. [CrossRef]

31. McKay, T.B.; Schlötzer-Schrehardt, U.; Pal-Ghosh, S.; Stepp, M.A. Integrin: Basement membrane adhesion by corneal epithelial and endothelial cells. *Eye Res. Exp. 2020*, *19*, 108138. [CrossRef]

32. Hou, L.; Fu, W.; Liu, Y.; Wang, Q.; Wang, L.; Huang, Y. Agrin Promotes Limbal Stem Cell Proliferation and Corneal Wound Healing Through Hippo-Yap Signaling Pathway. *Investig. Ophthalmol. Vis. Sci.* **2020**, *61*, 7. [CrossRef] [PubMed]

33. Li, Y.; Ge, L.; Chen, X.; Mao, Y.; Gu, X.; Ren, B.; Zeng, Y.; Chen, M.; Chen, S.; Liu, J.; et al. The common YAP activation mediates corneal epithelial regeneration and repair with different-sized wounds. *NPJ Regen. Med.* **2021**, *6*, 16. [CrossRef] [PubMed]

34. Wang, B.G.; Li, J.S.; Liu, Y.F.; Xu, Q. MicroRNA-200b suppresses the invasion and migration of hepatocellular carcinoma by downregulating RhoA and circRNA_000839. *Tumour. Biol.* **2017**, *39*, 1010428317719577. [CrossRef] [PubMed]
60. Rogge, M.; Yin, X.T.; Godfrey, L.; Lakireddy, P.; Potter, C.A.; Del Rosso, C.R.; Stuart, P.M. Therapeutic Use of Soluble Fas Ligand Ameliorates Acute and Recurrent Herpetic Stromal Keratitis in Mice. *Investig. Ophthalmol. Vis. Sci.* 2015, 56, 6377–6386. [CrossRef] [PubMed]

61. Aluru, S.V.; Shweta, A.; Bhaskar, S.; Geetha, K.; Sivakumar, R.M.; Upthal, T.; Padmanabhan, P.; Angayarkanni, N. Tear Fluid Protein Changes in Dry Eye Syndrome Associated with Rheumatoid Arthritis: A Proteomic Approach. *Ocul. Surf.* 2017, 15, 112–129. [CrossRef] [PubMed]

62. Tessitore, A.; Cicciarelli, G.; Mastroiacco, V.; Vecchio, F.D.; Capeo, D.; Fischietti, M.; Vecchiotti, D.; Zazzaroni, F.; Alessi, E. Therapeutic Use of MicroRNAs in Cancer. *Anticancer Agents Med. Chem.* 2016, 16, 7–19. [CrossRef] [PubMed]

63. Lam, J.K.; Chow, M.Y.; Zhang, Y.; Leung, S.W. siRNA Versus miRNA as Therapeutics for Gene Silencing. *Mol. Ther. Nucleic Acids* 2015, 4, e252. [CrossRef] [PubMed]

64. Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a New Era for the Management of Cancer and Other Diseases. *Nat. Rev. Drug Discov.* 2017, 16, 203–222. [CrossRef] [PubMed]

65. Zhou, S.S.; Jin, J.P.; Wang, J.Q.; Zhang, Z.G.; Freedman, J.H.; Zheng, Y.; Cai, L. miRNAs in cardiovascular diseases: Potential Biomarkers, Therapeutic Targets and Challenges. *Acta Pharmacol. Sin.* 2018, 39, 1073–1084. [CrossRef]

66. Shah, V.; Shah, J. Recent trends in targeting miRNAs for cancer therapy. *J. Pharm. Pharmacol.* 2020, 72, 1732–1749. [CrossRef]

67. Forterre, A.; Komuro, H.; Aminova, S.; Harada, M. A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. *Cancers* 2020, 12, 1852. [CrossRef]

68. Askou, A.L.; Alsing, S.; Holmgaard, A.; Bek, T.; Corydon, T.J. Dissecting microRNA dysregulation in age-related macular degeneration: New Targets for Eye Gene Therapy. *Acta Ophthalmol.* 2018, 96, 9–23. [CrossRef]

69. Mukwaya, A.; Jensen, L.; Peebo, B.; Lagali, N. MicroRNAs in the cornea: Role and implications for treatment of corneal neovascularization. *Ocul. Surf.* 2019, 17, 400–411. [CrossRef]

70. Liu, C.H.; Huang, S.; Britton, W.R.; Chen, J. MicroRNAs in Vascular Eye Diseases. *Int. J. Mol. Sci.* 2020, 21, 649. [CrossRef]

71. You, L.; Kruse, F.E.; Volcker, H.E. Neurotrophic factors in the human cornea. *Investig. Ophthalmol. Vis. Sci.* 2000, 41, 692–702. [PubMed]

72. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001, 25, 402–408. [CrossRef] [PubMed]

73. Vlachos, I.S.; Zagganas, K.; Paraskevopoulou, M.D.; Georgakilas, G.; Karagkouni, D.; Vergoulis, T.; Dalamagas, T.; Hatzigeorgiou, A.G. DIANA-miRPath v3.0: Deciphering microRNA Function with Experimental Support. *Nucleic Acids Res.* 2015, 43, W460–W466. [CrossRef] [PubMed]

74. Paraskevopoulou, M.D.; Georgakilas, G.; Kostoulas, N.; Vlachos, I.S.; Vergoulis, T.; Reczko, M.; Filippidis, C.; Dalamagas, T.; Hatzigeorgiou, A.G. DIANA-microT web server v5.0: Service Integration into miRNA Functional Analysis Workflows. *Nucleic Acids Res.* 2013, 41, W169–W173. [CrossRef] [PubMed]

75. Karagkouni, D.; Paraskevopoulou, M.D.; Chatzopoulos, S.; Vlachos, I.S.; Tatsosiou, S.; Kanellos, I.; Papadimitriou, D.; Kavakiotis, I.; Maniou, S.; Skoufos, G.; et al. DIANA-TarBase v8: A Decade-Long Collection of Experimentally Supported miRNA-Gene Interactions. *Nucleic Acids Res.* 2018, 46, D239–D245. [CrossRef]

76. Robinson, I.; Webber, J.; Eifrem, E. *Graph Databases*, 2nd ed.; O’Reilly Media, Inc.: Sebastopol, CA, USA, 2013.